These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27919292)

  • 1. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
    Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
    BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Jacobs IJ; Menon U; Ryan A; Gentry-Maharaj A; Burnell M; Kalsi JK; Amso NN; Apostolidou S; Benjamin E; Cruickshank D; Crump DN; Davies SK; Dawnay A; Dobbs S; Fletcher G; Ford J; Godfrey K; Gunu R; Habib M; Hallett R; Herod J; Jenkins H; Karpinskyj C; Leeson S; Lewis SJ; Liston WR; Lopes A; Mould T; Murdoch J; Oram D; Rabideau DJ; Reynolds K; Scott I; Seif MW; Sharma A; Singh N; Taylor J; Warburton F; Widschwendter M; Williamson K; Woolas R; Fallowfield L; McGuire AJ; Campbell S; Parmar M; Skates SJ
    Lancet; 2016 Mar; 387(10022):945-956. PubMed ID: 26707054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Singh N; Ryan A; Karpinskyj C; Carlino G; Taylor J; Massingham SK; Raikou M; Kalsi JK; Woolas R; Manchanda R; Arora R; Casey L; Dawnay A; Dobbs S; Leeson S; Mould T; Seif MW; Sharma A; Williamson K; Liu Y; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar M
    Lancet; 2021 Jun; 397(10290):2182-2193. PubMed ID: 33991479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
    Pavlik EJ
    Womens Health (Lond); 2016 Sep; 12(5):475-479. PubMed ID: 27595999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).
    Tsiachristas A; Gittins M; Kitchener H; Gray A
    J Med Screen; 2018 Jun; 25(2):99-109. PubMed ID: 28530515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.
    Ra H; Song LD; Choi JA; Jee D
    PLoS One; 2018; 13(10):e0206690. PubMed ID: 30379971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
    Manchanda R; Legood R; Pearce L; Menon U
    Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Fallowfield L; Solis-Trapala I; Menon U; Langridge C; May S; Jacobs I; Jenkins V
    Br J Cancer; 2017 Apr; 116(8):1111-1117. PubMed ID: 28324886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Naumann RW; Brown J
    Gynecol Oncol; 2018 Apr; 149(1):117-120. PubMed ID: 29398069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
    van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
    Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies.
    Sroczynski G; Gogollari A; Kuehne F; Hallsson LR; Widschwendter M; Pashayan N; Siebert U
    Cancer Prev Res (Phila); 2020 May; 13(5):429-442. PubMed ID: 32071120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the cost-effectiveness of pay-for-performance in primary care in the UK.
    Pandya A; Doran T; Zhu J; Walker S; Arntson E; Ryan AM
    BMC Med; 2018 Aug; 16(1):135. PubMed ID: 30153827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.